NasdaqGM - Delayed Quote • USD
Affimed N.V. (AFMD)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 5:41 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | -1.55 | -1.19 | -4.65 | -4.02 |
| Low Estimate | -1.95 | -1.63 | -6.63 | -5.43 |
| High Estimate | -0.65 | -0.54 | -2.49 | -2.66 |
| Year Ago EPS | -2.28 | -2.17 | -7.67 | -4.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 1.35M | 1.18M | 5.04M | 5.52M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 3.42M | 3.18M | 10.82M | 11.14M |
| Year Ago Sales | 5.06M | 1.47M | 8.95M | 5.04M |
| Sales Growth (year/est) | -73.30% | -19.70% | -43.70% | 9.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.12 | -2.06 | -2 | -1.67 |
| EPS Actual | -2.28 | -2.17 | -1.74 | -1.46 |
| Difference | -0.16 | -0.11 | 0.26 | 0.21 |
| Surprise % | -7.50% | -5.30% | 13.00% | 12.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.55 | -1.19 | -4.65 | -4.02 |
| 7 Days Ago | -1.7 | -1.31 | -5.03 | -4.03 |
| 30 Days Ago | -1.69 | -1.29 | -4.98 | -3.99 |
| 60 Days Ago | -1.71 | -1.42 | -5.3 | -3.84 |
| 90 Days Ago | -0.15 | -0.13 | -0.62 | -0.53 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AFMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 32.00% | -- | -- | 9.10% |
| Next Qtr. | 45.20% | -- | -- | 11.50% |
| Current Year | 39.40% | -- | -- | 5.70% |
| Next Year | 13.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/25/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/12/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Truist Securities: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Related Tickers
BPTH Bio-Path Holdings, Inc.
2.4800
-10.79%
ANNX Annexon, Inc.
5.74
-2.55%
VRAX Virax Biolabs Group Limited
1.9700
0.00%
FGEN FibroGen, Inc.
1.1000
-7.56%
GPCR Structure Therapeutics Inc.
53.07
-4.60%
VNDA Vanda Pharmaceuticals Inc.
6.12
-2.39%
SMMT Summit Therapeutics Inc.
7.72
-5.04%
BMEA Biomea Fusion, Inc.
4.1400
-63.27%
GERN Geron Corporation
4.5900
+17.99%
BCDA BioCardia, Inc.
3.7200
-14.87%